AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

2019 Pipeline Insight on Restless Legs Syndrome - Analysis by Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com

February 27, 2019

DUBLIN--(BUSINESS WIRE)--Feb 27, 2019--The “Restless Legs Syndrome - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Restless Legs Syndrome development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for the Restless Legs Syndrome
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Restless Legs Syndrome
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Restless Legs Syndrome
  • The report also covers the dormant and discontinued pipeline projects related to Restless Legs Syndrome

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Restless Legs Syndrome to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Restless Legs Syndrome therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Companies Mentioned

  • Galenica Ltd.
  • Hisamitsu Pharmaceutical Co. Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Mundipharma International Ltd.
  • Omeros Corp.
  • Serina Therapeutics Inc.

Topics Covered

1. Report Introduction

2. Restless Legs Syndrome Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Restless Legs Syndrome

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jvrz4t/2019_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190227005777/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/27/2019 12:59 PM/DISC: 02/27/2019 12:59 PM

http://www.businesswire.com/news/home/20190227005777/en